Company Overview and News

 
SPC downplays impact of Naga power plant turnover

2018-07-18 bworldonline
SPC Power Corp. has downplayed the impact on the company of the recent turnover of a power plant complex in Naga City, Cebu to another group after their legal battle resulted against its favor.
ABZPF ABZPY SPC AP

 
SPC turns over Naga power plant complex to PSALM

2018-07-16 bworldonline
SPC Power Corp. has turned over the 153.1-megawatt (MW) gas turbine power plant in Naga, Cebu to the Power Sector Assets Liabilities Management, Inc. (PSALM), ending the legal tussle over the ownership of the asset.
ABZPF ABZPY SPC AP

 
How safe are utility stocks in a market downturn?

2018-07-10 business.inquirer.net
Investing in utility stocks has been traditionally regarded as a classic defensive strategy, especially in times of market volatility, because utilities are relatively more stable than nonutility stocks.
ABZPF MWC ABZPY SPC AP

4
TPVI cleared to buy Naga plant

2018-05-25 bworldonline
ABOITIZ POWER Corp. said in Thursday that its subsidiary had received regulatory certification to initiate the purchase of a power plant in Naga City, Cebu.
ABZPF ABZPY SPC AP

16
Tech businesses powering Asia-Pacific growth

2018-04-05 bworldonline
London’s venerable Financial Times (FT) recently released its first-ever “FT 1000 High-Growth Companies Asia-Pacific” list — with 26 Filipino firms making the grade, all of which are listed on the Philippine Stock Exchange except for one.
JGSMY CNPF JGS ATI SGI CEBUY TUGS ACR SSI JBFCF MWP PHSXY H2O LNSTY PSE MWIDE CEB AISNY JGSHF CIC PSKXF JBFCY PRGLY PGOLD MBC PGCMF CROWN TECH STI CEBUF SPC JFC PERC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PSE:SPC / SPC Power Corporation on message board site Silicon Investor.

SSPC Moderated Forum SSPC Moderated Forum SSPC Moderated Forum SSPC: Southern States Power Co. SSPC: Southern States Power Co. SSPC: Southern States Power Co.
SPCI - SPORTSNUTS.COM INTL INC SPCI - SPORTSNUTS.COM INTL INC SPCI - SPORTSNUTS.COM INTL INC Spectrian Co. (SPCT) Spectrian Co. (SPCT) Spectrian Co. (SPCT)
Spectrum Resourse Spectrum Resourse Spectrum Resourse Software Publishing(SPCOD) Software Publishing(SPCOD) Software Publishing(SPCOD)
Aspec Technology (ASPC) Aspec Technology (ASPC) Aspec Technology (ASPC) DSP Communications (DSP, Formerly DSPC) DSP Communications (DSP, Formerly DSPC) DSP Communications (DSP, Formerly DSPC)
SSPC A FUEL CELL STOCK ? SSPC A FUEL CELL STOCK ? SSPC A FUEL CELL STOCK ? SPCO - SOFTWARE PUBLISHING CORPORATION SPCO - SOFTWARE PUBLISHING CORPORATION SPCO - SOFTWARE PUBLISHING CORPORATION